12:00 AM
Jul 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Collagenase clostridium histolyticum: Phase II started

BioSpecifics began an open-label, dose-escalation Phase II trial to evaluate single injections of 0.058, 0.15, 0.29 and 0.44 mg Xiaflex in about 14 lipoma patients. The product is approved in the U.S. as Xiaflex and as Xiapex in the EU to treat...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >